Related Experiment Video
Updated: Jan 7, 2026

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
Evaluation of programmed cell death ligand-1 expression in primary central nervous system lymphoma using whole-tumor
Xiaofang Zhou1,2, Xiaoli Su3,4, Lan Yu1,2
1Department of Radiology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Objective:
To assess the diagnostic performance of whole-tumor histogram analysis of multiparametric MRI in predicting programmed cell death ligand-1 (PD-L1) expression in primary central nervous system lymphoma (PCNSL).
Methods:
A total of 130 patients with PCNSL (61 males, aged 21-80 years) were included in the study. Histogram features derived from T2-weighted imaging (T2WI), T1-weighted imaging (T1WI), fluid-attenuated inversion recovery (FLAIR), contrast-enhanced T1-weighted imaging (T1WI+C), and apparent diffusion coefficient (ADC) were compared between the low and high PD-L1 expression groups using the Mann-Whitney U test. Receiver operating characteristic (ROC) curves and logistic regression analysis were applied to assess the diagnostic performance of both individual and combined models in predicting PD-L1 expression levels in PCNSL.
Results:
Eighteen histogram features extracted from multiparametric MRI exhibited significant differences between high and low PD-L1 expression in PCNSL (all P < 0.05). The predictive performance of single-sequence models was relatively modest, with areas under the curve (AUC) ranging from 0.637 to 0.705, and no significant differences were observed between these models (all P > 0.05). The combined model demonstrated the highest diagnostic performance (AUC = 0.809), significantly outperforming the single-sequence models (all P < 0.05).
Conclusions:
Whole-tumor histogram analysis of multiparametric MRI shows potential as a non-invasive method for evaluating PD-L1 expression in PCNSL, which may assist in the identification of immunotherapy-eligible patients.

